Maze Therapeutics swaps 2,776,007 Frazier-held shares for pre-funded warrants

Maze Therapeutics, Inc. (Nasdaq: MAZE) entered into an exchange agreement on October 15, 2026 with four Frazier Life Sciences funds, which the filing calls the Exchanging Stockholder. Maze exchanged an aggregate of 2,776,007 shares of its common stock held by the funds for pre-funded warrants to buy the same number of shares. The warrants have an exercise price of $0.001 per share. A pre-funded warrant is a warrant whose price is almost entirely paid up front, so the holder pays only a nominal amount to receive the shares.

After the exchange, Maze had 53,931,889 shares of common stock outstanding as of October 16, 2026.

The warrants can be exercised at any time after issuance. The Exchanging Stockholder cannot exercise them if it would then beneficially own more than 9.99% of the outstanding common stock, subject to certain exceptions. Holders of the warrants have no right to vote the underlying shares except as Delaware law requires.

Maze said it will issue the warrants without registration under the Securities Act of 1933, relying on the exemption in Section 3(a)(9). The company reported the exchange in an 8-K filed October 16, 2026 under Items 1.01 and 3.02.

Report an error